NovaBridge Biosciences
NBP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001778016
In the last 90 days, NovaBridge Biosciences insiders filed 0 open-market purchases and 4 sales; 49 institutions reported holding it in 13F filings for Q2 2026, worth $48.1M in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
13F holders, Q2 2024
Institutional positions in NovaBridge Biosciences as of Jun 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 38
- −1 vs. Q1 2024
- Shares held
- 15.1M
- +2.95M (+24.2%) vs. Q1 2024
- Total value
- $25.3M
- +$2.65M (+11.7%) vs. Q1 2024
- New holders
- 3
- 5 more added
- Sold out
- 4
- 18 more reduced
Compare with Q1 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting NBP on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 49 | $48.1M |
| Q1 2026 | 48 | $72.1M |
| Q4 2025 | 57 | $132.1M |
| Q3 2025 | 42 | $112.3M |
| Q2 2025 | 32 | $22.7M |
| Q1 2025 | 29 | $7.41M |
| Q4 2024 | 28 | $10.1M |
| Q3 2024 | 28 | $17.6M |
| Q2 2024 | 38 | $25.3M |
| Q1 2024 | 39 | $22.7M |
| Q4 2023 | 44 | $23.5M |
| Q3 2023 | 47 | $20.1M |
| Q2 2023 | 48 | $55.9M |
| Q1 2023 | 53 | $71.6M |
| Q4 2022 | 69 | $103.9M |
| Q3 2022 | 75 | $123.3M |
| Q2 2022 | 97 | $430.3M |
| Q1 2022 | 120 | $654.5M |
| Q4 2021 | 132 | $1.85B |
| Q3 2021 | 145 | $2.61B |
| Q2 2021 | 136 | $2.38B |
| Q1 2021 | 80 | $1.13B |
Institutions, Q2 2024
Shares, value and share of portfolio for each institution holding NovaBridge Biosciences; share changes are against Q1 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Royal Bank of Canada | 145 | $0 | 0.00% | −1,499−91.2% | Reduced |
| Citigroup Inc | 50 | $84 | 0.00% | 00.0% | Unchanged |
| GAMMA Investing LLC | 63 | $105 | 0.00% | 00.0% | Unchanged |
| Catalyst Funds Management Pty Ltd | 90 | $150 | 0.00% | −146,200−99.9% | Reduced |
| Frazier Financial Advisors, LLC | 515 | $861 | 0.00% | +140+37.3% | Added |
| Bank of America Corp | 568 | $949 | 0.00% | −18,289−97.0% | Reduced |
| Legal & General Group Plc | 1,191 | $1.99K | 0.00% | 00.0% | Unchanged |
| Rhumbline Advisers | 1,367 | $2.28K | 0.00% | −4−0.3% | Reduced |
| Qube Research & Technologies Ltd | 2,565 | $4.28K | 0.00% | −1,500−36.9% | Reduced |
| BlackRock Inc. | 7,684 | $12.8K | 0.00% | −239−3.0% | Reduced |
| UBS Group AG | 12,514 | $20.9K | 0.00% | +11,183+840.2% | Added |
| Morgan Stanley | 13,880 | $23.2K | 0.00% | +3,771+37.3% | Added |
| Marshall Wace, LLP | 14,064 | $23.5K | 0.00% | −57,024−80.2% | Reduced |
| Goldman Sachs Group Inc | 15,750 | $26.3K | 0.00% | −69,191−81.5% | Reduced |
| XTX Topco Ltd | 17,876 | $29.9K | 0.00% | −12,609−41.4% | Reduced |
| Donald L. Hagan, LLC | 30,000 | $50.1K | 0.03% | 00.0% | Unchanged |
| Barclays PLC | 30,370 | $50.7K | 0.00% | −8,182−21.2% | Reduced |
| Susquehanna International Group, LLP | 31,066 | $51.9K | 0.00% | +31,066 | New |
| Mariner, LLC | 31,535 | $52.7K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 34,347 | $57.4K | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 38,708 | $64.6K | 0.00% | +38,708 | New |
| Millennium Management LLC | 40,308 | $67.3K | 0.00% | −53,200−56.9% | Reduced |
| Invesco Ltd. | 57,933 | $96.7K | 0.00% | −27,211−32.0% | Reduced |
| Dimensional Fund Advisors LP | 58,358 | $97.5K | 0.00% | −2,049−3.4% | Reduced |
| Renaissance Technologies LLC | 63,800 | $106.5K | 0.00% | 00.0% | Unchanged |
| Alberta Investment Management Corp | 74,723 | $124.8K | 0.00% | 00.0% | Unchanged |
| State Street Corp | 102,961 | $171.9K | 0.00% | −7,412−6.7% | Reduced |
| Standard Life Aberdeen plc | 162,580 | $271.5K | 0.00% | 00.0% | Unchanged |
| EDBI Pte Ltd | 222,136 | $371.0K | 0.42% | 00.0% | Unchanged |
| Bank of Montreal | 244,875 | $453.0K | 0.00% | +244,875 | New |
| Exome Asset Management LLC | 271,400 | $453.2K | 0.40% | −54,362−16.7% | Reduced |
| Gsa Capital Partners LLP | 272,193 | $455.0K | 0.03% | −160,428−37.1% | Reduced |
| Two Sigma Investments, LP | 478,442 | $799.0K | 0.00% | −97,138−16.9% | Reduced |
| Temasek Holdings (Private) Ltd | 566,650 | $946.3K | 0.00% | 00.0% | Unchanged |
| Two Sigma Advisers, LP | 576,600 | $962.9K | 0.00% | −40,500−6.6% | Reduced |
| Boothbay Fund Management, LLC | 1,379,352 | $2.30M | 0.07% | +1,001,083+264.6% | Added |
| Caligan Partners LP | 3,374,791 | $5.64M | 1.32% | +2,618,253+346.1% | Added |
| HHLR Advisors, Ltd.SuperinvestorHHLR Advisors (Hillhouse) | 6,909,220 | $11.5M | 0.28% | 00.0% | Unchanged |
| Man Group plc | 0 | $0 | 0.00% | −134,977−100.0% | Sold out |
| Prelude Capital Management, LLC | 0 | $0 | 0.00% | −81,262−100.0% | Sold out |
| Atom Investors LP | 0 | $0 | 0.00% | −29,612−100.0% | Sold out |
| Simplex Trading, LLC | 0 | $0 | 0.00% | −84−100.0% | Sold out |